Therapeutic possibilities of botulinum toxin in neurological disorders – treatment of limb spasticity in the course of brain damage
DOI:
https://doi.org/10.15584/ejcem.2019.3.10Keywords:
botulinum toxin, neurology, spasticityAbstract
Introduction. Botulinum toxin is produced by the anaerobic bacterium Clostridium botulinum. The sporulation form of the C. botulinum is widely found in the environment (in soil) and may develop in inappropriately stored food. The symptoms of poisoning occur 18-36 hours after consumption of contaminated food.
Aim. The aim of this study is to present the benefits of using botulinum toxin in the treatment of spasticity of the upper and lower limbs in both adults and children.
Material and methods. A literature review of the following databases was carried out: PubMed, UpToDate.
Results. Botulinum toxin interferes with neural transmission by blocking the release of acetylcholine and causes muscle paralysis. The typical symptoms are diplopia, xerostomia, enteroparesis, speaking and swallowing disorders, as well as paralysis of respiratory muscles which leads to death. However, botulinum toxin is also a very potent medication. The biggest application is found in the field of neurology, inter alia, in the treatment of spasticity.
Conclusion. The study provides current evidence regarding the safety and efficacy of botulinum toxin injection for spasticity of the upper and lower limbs. Botulinum toxin injections are applicable in the treatment of many neurological disorders and the list of indications will certainly become wider.
Downloads
References
Dressler D, Roggenkaemper P. A brief history of neurological botulinum toxin therapy in Germany. J Neural Transm (Vienna). 2017;124(10):1217-1221.
Santamato A, Cinone N, Panza F, et al. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs. 2019;79(2):143-160.
Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat. 2007;3(6):785-798.
UpToDate. Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues. https://www.uptodate.com/contents/cerebral-palsy-treatment-of-spasticity-dystonia-and-associated-orthopedic-issues. Updated January 04, 2019. Accessed March 29, 2019.
Matak I, Lackovic Z. Botulinum neurotoxin type A: Actions beyond SNAP-25? Toxicology. 2015;335:79-84.
Tater P, Pandey S. Botulinum toxin in movement disorders. Neurol India. 2018;66(Supplement):79-89.
Orsini M, Leite MA, Chung TM, et al. Botulinum Neurotoxin Type A in Neurology: Update. Neurol Int. 2015;7(2):5886.
Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr. Neurol. Neurosci. Rep. 2010;10(5):338-344.
Moawad EM, Abdallah EA. Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life. GPH. 2015;2:2333794x15590149.
Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939.
Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3-9.
Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017;9(9).
Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-14.
Schrader C, Ebke M, Adib Saberi F, Dressler D. Botulinum toxin therapy in patients with oral anticoagulation: is it safe? J Neural Transm (Vienna). 2018;125(2):173-176.
Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275-290.
Rasetti-Escargueil C, Lemichez E, Popoff MR. Variability of Botulinum Toxins: Challenges and Opportunities for the Future. Toxins (Basel). 2018;10(9).
Kaku M, Simpson DM. Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity. Drug Des Devel Ther. 2016;10:1085-1099.
Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629-1648.
Buyukavci R, Akturk S, Ersoy Y. Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients: an observational study. Eur J Phys Rehabil Med. 2018;54(5):738-744.
Kaymak B, Kara M, Tok F, et al. Sonographic guide for botulinum toxin injections of the lower limb: EUROMUSCULUS/USPRM spasticity approach. Eur J Phys Rehabil Med. 2018;54(3):486-498.
Kara M, Kaymak B, Ulasli AM, et al. Sonographic guide for botulinum toxin injections of the upper limb: EUROMUSCULUS/USPRM spasticity approach. Eur J Phys Rehabil Med. 2018;54(3):469-485.
Nesbitt-Hawes EM, Dietz HP, Abbott JA. Four-dimensional ultrasound guidance for pelvic floor Botulinum toxin-A injection in chronic pelvic pain: a novel technique. Ultrasound Obstet Gynecol. 2018;51(3):396-400.
Werdelin L, Dalager T, Fuglsang-Frederiksen A, et al. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol. 2011;122(11):2305-2309.
Basar E, Arici C. Use of Botulinum Neurotoxin in Ophthalmology. Turk J Ophthalmol. 2016;46(6):282-290.
Lennerstrand G, Nordbo OA, Tian S, Eriksson-Derouet B, Ali T. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998;76(1):27-27.
Brisinda G, Sivestrini N, Bianco G, Maria G. Treatment of gastrointestinal sphincters spasms with botulinum toxin A. Toxins (Basel). 2015;7(6):1882-1916.
Liu JY, Zheng ZQ, Zhao K, Luo C, Han HQ. Treatment of Adult Hirschsprung's Disease by Botulinum Toxin A through Anorectal Injection. Chin. Med. J. 2018;131(24):3007-3008.
Rodriguez L, Rosen R, Manfredi M, Nurko S. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointest. Endosc. 2012;75(2):302-309.
Sandrini G, Baricich A, Cisari C, Paolucci S, Smania N, Picelli A. Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey. Funct. Neurol. 2018;33(1):37-43.
Gracies JM, Esquenazi A, Brashear A, et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22):2245-2253.
Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity. Medicine (Baltimore). 2016;95(2):e2468.
Syed YY. AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity. Paediatr Drugs. 2017;19(4):367-373.
Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin((R))] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur. J. Paediatr. Neurol. 2016;20(4):532-537.
Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity. Am J Phys Med Rehabil. 2015;94(3):229-238.
Franzen M, Hagglund G, Alriksson-Schmidt A. Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study. BMC Musculoskelet Disord. 2017;18(1):520.
Juneja M, Jain R, Gautam A, Khanna R, Narang K. Effect of multilevel lower-limb botulinum injections & intensive physical therapy on children with cerebral palsy. Indian J. Med. Res. 2017;146(Supplement):8-14.
Matsuda M, Tomita K, Yozu A, et al. Effect of botulinum toxin type A treatment in children with cerebral palsy: Sequential physical changes for 3months after the injection. Brain Dev. 2018;40(6):452-457.
Buyukavci R, Buyukavci MA. Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. Acta Neurol Belg. 2018;118(3):429-433.
Mirska A, Kulak W, Okurowska-Zawada B, Dmitruk E. Effectiveness of multiple botulinum toxin sessions and the duration of effects in spasticity therapy in children with cerebral palsy. Childs Nerv Syst. 2019;35(1):141-147.
Akturk S, Buyukavci R, Ersoy Y. Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients. Toxicon. 2018;146:95-98.
Ianieri G, Marvulli R, Gallo GA, Fiore P, Megna M. "Appropriate Treatment" and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units. Toxins (Basel). 2018;10(4).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
